Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Nat Med · 2023 · PMC10504071 · PMID 37592106

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

The nadir of sBCMA levels after ide-cel infusion was lower in responding patients, and there was a numerical trend toward increasing depth of sBCMA clearance in the peripheral blood (PB) with longer DOR; however, no clear trend was seen between median sBCMA nadir and best overall response (Fig. 2a ).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.